On Tuesday evening, Abliva announced a licensing and collaboration deal with US-based Owl Therapeutics for the development of NeuroSTAT for Traumatic Brain Injury. The deal includes potential milestone payments of 43,65 MUSD. BioStock reached out to Abliva's CEO Ellen K. Donnelly for a comment.

Read the article at biostock.se:

https://www.biostock.se/en/2023/11/abliva-signs-global-license-deal-for-neurostat/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/abliva/r/biostock-abliva-signs-global-license-deal-for-neurostat,c3877115

(c) 2023 Cision. All rights reserved., source Press Releases - English